Transgenic Amyloid Models
Test putative Alzheimer’s disease therapeutics using in vivo models with amyloid beta plaque deposition and the downstream pathological events
The histopathological hallmarks of Alzheimer’s disease (AD) are extracellular plaques composed of Amyloid Beta (Aβ) and intracellular inclusions of the protein Tau (neurofibrillary tangles). Cleavage of the amyloid precursor protein (APP) leads to the generation of amyloid beta (Aβ) protein fragments.
Mouse models of amyloid pathology (over)express the human APP with familial AD-related mutations. These mouse models recapitulate the Aβ aggregation cascade by expressing higher levels of the toxic Aβ1-40 and Aβ1-42 peptides. The biological and associated behavioural deficits observed in amyloid models make them a valuable model of AD, suitable for drug-screening studies.
Take advantage of InnoSer’s expertise, flexibility and collaborative approach for your research. Our in-house neurology experts have a long-standing experience with modelling AD in vivo and are happy to help guide your decision on choosing the best model fit for your current research goals.
Transgenic amyloid models that InnoSer offers:
- APP/PS1 (ARTE10)
- APPSWE (Tg2576)
- Humanized APP (APP-SAA Targeted Replacement)
Find the right model for you.
Compare our model capabilities and discover which of our neurology platforms suits your research needs
Test the efficacy of your treatments in the following battery of cognitive behavioural tests:
- CognitionWall Discrimination learning
- Morris water maze
- 8-arm radial maze test
- Fear conditioning
- Nesting test
- T maze spontaneous alteration.
- MSD: Plasma, CSF, and brain (e.g., Aβ, cytokines, NfL).
- (Digital) histopathology
- Immunohistochemistry (e.g., Aβ plaques, phosphorylated Tau, microglia & astrocyte activation)
- Immunofluorescence and FISH
Amyloid mouse models show an impaired cognitive performance during the CognitionWall™ Discrimination learning
This deficit is already apparent at 12 weeks of age, before the appearance of plaques (~26 weeks). At 16 weeks, this deficit in discrimination learning can be rescued by an acute dose of the BACE1 inhibitor LY2886721. Using the CognitionWall™, we developed a one-night automated test to efficiently identify discrimination learning impairments in mice, without time-consuming handling of mice. The CognitionWall™ is a wall with three entrances in front of a food dispenser. Mice are rewarded with a food reward when they choose to pass through one of the three entrances. The rate at which a mouse gains a relative preference for the rewarded entrance is used as a measure of discrimination learning.
BACE1 inhibitors lower Aβ levels in plasma and brain
The number and size of amyloid plaques and associated neuroinflammation can be quantified after immunohistochemical (IHC) staining of brain slices. Aβ levels can be quantified in the brain, cerebrospinal fluid, and blood using ultra-sensitive immunoassays.
ARTE10 mice show progressive Aβ plaques (X04) and astrogliosis
In ARTE10 mice, methoxy-X04-positive amyloid plaque deposition is detected at 6 months (6M) of age, which becomes more pronounced at 10 months of age (10M). This is associated with reactive astrocytes (GFAP) around the plaques.
Reactive microglia around plaques in ARTE10 mice
Iba1 (general microglia marker), shows clusters of microglia in ARTE10 mice. CD11B (neuroinflammation-related microglia marker) shows increases signal around plaques. MHC-II (neuroinflammation-related microglia marker) shows increased signal around the plaques.
Related Alzheimer’s disease model options
Neurology Platform Overview
Transgenic Tau Models
Tau Seeding Model
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Need more information?
If you have any questions about how we can help accelerate your research,
then let us know